Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Wyeth is now a wholly owned subsidiary of Pfizer480 enrolled

Overview

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Study Type

OBSERVATIONAL

Enrollment

480

Conditions

Escherichia Coli Infections Klebsiella Infections

Interventions

vancomycin-resistant enterococci and ESBLDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients admitted to or transferred to the MICU. * Patients 18 years of age or older. * Provide written informed consent. Exclusion Criteria: * Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae. * Patients who have hypersensitivity to penicillin. * Any underlying conditions or diseases that will be ultimately fatal within 48 hours. * Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Locations (1)

Unnamed facility

Gyunggi-do, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.